Yasuo Fujii
Directeur/Membre du Conseil chez ORCHARD THERAPEUTICS PLC
Postes actifs de Yasuo Fujii
Sociétés | Poste | Début | Fin |
---|---|---|---|
KYOWA KIRIN CO. LTD. | Corporate Officer/Principal | 01/04/1988 | - |
ORCHARD THERAPEUTICS PLC | Directeur/Membre du Conseil | 24/01/2024 | - |
Historique de carrière de Yasuo Fujii
Anciens postes connus de Yasuo Fujii
Sociétés | Poste | Début | Fin |
---|---|---|---|
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Corporate Officer/Principal | 01/09/2012 | - |
Formation de Yasuo Fujii
University of Illinois | Masters Business Admin |
Statistiques
Internationale
Royaume-Uni | 3 |
Japon | 2 |
Etats-Unis | 2 |
Opérationnelle
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Director/Board Member | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
KYOWA KIRIN CO. LTD. | Health Technology |
Entreprise privées | 2 |
---|---|
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Yasuo Fujii
- Expérience